arrow
E

Eduardo Martínez de Dueñas

castellón de la plana
H指数:31
被引数:4,376

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trial

帕博西利和曲妥珠单抗用于HER2阳性转移性乳腺癌:SOLTI-1303-PATRICIA试验A组和B组的最终总生存结果

2025-09-010
OAAI
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak

TIM3⁺乳腺癌细胞在微转移爆发期间促进免疫逃逸

2025-07-100
OAAI
Key landmarks of male advanced breast cancer: Results of the GEICAM/2016-04 study

男性晚期乳腺癌的关键里程碑:GEICAM/2016-04研究的结果

2024-09-010
PRE
Impact of coadministration of proton-pump inhibitors and palbociclib in hormone receptor-positive/HER2-negative advanced breast cancer
BREAST
IF7.9
2024-08-010
OAAI
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/ PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

使用二甲双胍预防HR /HER2-/ PIK3CA-mutated晚期乳腺癌中与alpelisib相关的高血糖症 (METALLICA): 一项多中心,开放标签,单臂,2期试验

2024-05-011
OAAI
Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study
2023-03-016
PRE
Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2-ABC): Exploratory Analysis of the PARSIFAL Trial
2023-03-011
PRE
Overall survival in the OlympiA phase Ill trial of adjuvant olaparib in patients with germime pathogenic variants in BRCA1/2 and high-risk, early breast cancer

OlympiA iii期试验中辅助olaparib治疗BRCA1/2中germime致病变异和高危早期乳腺癌患者的总生存率

2022-12-01198
OAAI
PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab HER2-positive breast cancer: Survival results of the SOLTI-PAMELA study
2022-05-011
OA
Palbociclib and trastuzumab for HER2-positive metastatic breast cancer (SOLTI-1303 PATRICIA): Final results from cohort A and B, prospective, open-label, multicenter phase II study
2022-02-150
PRE
SOLTI-1303 PATRICIA 2 randomized phase II trial of palbociclib plus trastuzumab and endocrine therapy (ET) versus treatment of physician's choice (TPC) in metastatic HER2-positive and hormone receptor-positive (HER2+/HR+) breast cancer (BC) with PAM50 luminal intrinsic subtype
2021-05-011
OA
Metformin (MF) in the prevention of hyperglycemia (HG) in patients (pts) with PIK3CA-mutated, hormone receptor (HR) [+]/HER2[-] advanced breast cancer (ABC) treated with alpelisib (ALP) plus fulvestrant (F): METALLICA
2021-05-011
OA
Expression of ERBB2 and PD1 mRNA in advanced gastric cancer
2020-09-010
OAAI
FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease

FGFR4调节管腔型乳腺癌和转移性疾病的肿瘤亚型分化

2020-08-1758
OA